An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Trial Status: active
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene
alterations, including locally advanced/metastatic urothelial carcinoma of the bladder
and urinary tract and other advanced solid tumors.
Inclusion Criteria
Inclusion Criteria:
Phase 1 Part A and Part B
- Men and women 18 years of age or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
- Histologically confirmed advanced solid tumor who have exhausted standard
therapeutic options.
- Evaluable (Part A) or measurable (Part B) disease according to RECIST v1.1.
- Histologically confirmed advanced solid tumor with an eligible FGFR3 gene mutation
or fusion (Part B).
Phase 2
- Men and women 18 years of age or older.
- ECOG performance status of 0-2 or Karnofsky Performance Scale (KPS) >70.
- At least 1 measurable lesion by RECIST v1.1.
- Histologically confirmed locally advanced/metastatic tumor in one of the following
categories:
- Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who
have progressed on a prior FGFR inhibitor and presence of a resistance mutation
or other kinase domain mutation.
- Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who
has not received a prior FGFR inhibitor.
- Any solid tumor with an eligible FGFR3 gene mutation or rearrangement.
Exclusion Criteria (All Phases):
- Has a serum phosphorus level > upper limit of normal (ULN) during screening that
remains >ULN despite medical management.
- Any ocular condition likely to increase the risk of eye toxicity.
- History of or current uncontrolled cardiovascular disease.
- Active, symptomatic, or untreated brain metastases.
- Gastrointestinal disorders that will affect oral administration or absorption of
TYRA-300.
- Females who are pregnant, breastfeeding, or planning to become pregnant and males
who plan to father a child while enrolled in this study.
Additional locations may be listed on ClinicalTrials.gov for NCT05544552.
